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Abstract
Objectives: 1) To design and validate indicators to measure the quality of the process of care that climacteric
stage women receive in family medicine clinics (FMC). 2) To assess the quality of care that climacteric stage
women receive in FMC. 3) To determine the association between quality of care and health-related quality of life
(HR-QoL) among climacteric stage women.
Methods: The study had two phases: I. Design and validation of indicators to measure the quality of care process
by using the RAND/UCLA Appropriateness Method. II. Evaluation of the quality of care and its association with HR-
QoL through a cross-sectional study conducted in two FMC located in Mexico City that included 410 climacteric
stage women. The quality of care was measured by estimating the percentage of recommended care received
(PRCR) by climacteric stage women in three process components: health promotion, screening, and treatment. The
HR-QoL was measured using the Cervantes scale (0-155). The association between quality of care and HR-QoL was
estimated through multiple linear regression analysis.
Results: The lowest mean of PRCR was for the health promotion component (24.1%) and the highest for the
treatment component (86.6%). The mean of HR-QoL was 50.1 points. The regression analysis showed that in the
treatment component, for every 10 additional points of the PRCR, the global HR-QoL improved 2.8 points on the
Cervantes scale (coefficient -0.28, P < 0.0001).
Conclusion: The indicators to measure quality of care for climacteric stage women are applicable and feasible in
family medicine settings. There is a positive association between the quality of the treatment component and HR-
QoL; this would encourage interventions to improve quality of care for climacteric stage women.
Introduction
The climacteric stage is the transition from the repro-
ductive to the non-reproductive period during the life of
women [1], and comprises 2-8 years before and after
menopause [2]. During the climacteric stage, the decline
in ovarian hormones and aging contribute to the
appearance of climacteric symptoms, decrease in bone
mass density, and increase in chronic diseases [2].
This complex scenario may negatively affect the
woman’s health-related quality of life (HR-QoL) [3] and
increases her need for health services [4]. The definition
of HR-QoL is as follows: “the perception of a person
about his/her physical and psychological health, level of
independence and social relationships” [5]. HR-QoL is a
proxy for health status, and an outcome variable of epi-
demiological, clinical, and health systems research stu-
dies; it is also an independent predictor for the analysis
of the use and cost of health services [6,7].
Measuring the HR-QoL is relevant during the climac-
teric stage. Hot flashes and sweating can cause anxiety,
social isolation, and difficulties at work, which in turn
affects HR-QoL [3,8]. Factors such as older age, lack of
p a r t n e ra n d / o rc h i l d r e n ,u n favorable socioeconomic
conditions, low social support, presence of chronic
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with low HR-QoL as well [9-11].
Reports from clinical trials have shown that hormone
therapy (HT) decreases climacteric symptoms and has a
positive effect on HR-QoL [9,12,13]. However, there are
no studies aimed at measuring the quality of health care
that climacteric stage women receive and its relationship
with HR-QoL.
T h eq u a l i t yo fh e a l t hc a r ei sam u l t i d i m e n s i o n a lc o n -
cept that includes “the degree to which health services
for individuals and populations increase the likelihood
of desired health outcomes and are consistent with cur-
rent professional knowledge” [14]. The approach to
assess quality should address either individual or popu-
lation perspectives; in both, it is appropriate to include
in the assessment any of the usual three dimensions:
structure, process, and outcomes [15].
Process of care is the actual provision and reception of
care through interactions between users and providers. At
the individual level, measuring the quality of the process
of care through indicators is a robust approach [16]. The
indicators can measure different components of the pro-
cess of care, and should be constructed upon standards of
care that follow systematic methods based on scientific
evidence and/or expert opinion, and should be replicable.
The indicators allow valid judgments of the quality of care
to be reached and, although they do not provide definitive
answers, allow the identification of potential problems
during the provision of health care [17].
The growing number of climacteric stage women and
the increasing body of knowledge about the complexity
of their health needs are raising new requirements for
health services.
Health care for climacteric stage women should be
comprehensive. This comprises the provision of hor-
mone therapy (HT) when appropriate for climacteric
symptoms, and should include counseling about climac-
teric and menopause, promotion of a healthy lifestyle,
and screening, diagnosis, and treatment of chronic dis-
eases. These components must fulfill standards of care
that can meet the expectation to achieve a positive effect
on the health status and HR-QoL of women.
To build up the evidence on this topic, this study had
the following objectives: 1) To design and validate indica-
tors to measure the quality of the process of care that cli-
macteric stage women receive in family medicine clinics.
2) To assess the quality of care that climacteric stage
women receive in family medicine clinics. 3) To deter-
mine the association between quality of care and health-
related quality of life among climacteric stage women.
Methods
The study was conducted in two phases: I. Design and
validation of indicators to measure the quality of care
that climacteric stage women receive in family medicine
clinics. II. Assessment of the quality of care and of its
association with HR-QoL in climacteric stage women.
Phase I
To design and validate indicators, we used the modified
version of the RAND/UCLA Appropriateness Method
[18]. This method combines expert opinion and sys-
tematic literature review of scientific evidence [19].
The method comprised the following activities:
i) Systematic search and review of the literature to
collect scientific evidence regarding the care process
activities that climacteric stage women should receive at
the family medicine clinic. The databases of Medline,
Ovid, Cochrane Library, National Institute for Clinical
Excellence, and World Health Organization covering the
period 1990-2008 were consulted. The entries for the
search were “climacteric” and/or “menopausal” and/or
“postmenopausal women,”“ quality of care indicators”
and “guidelines,” and “family medicine clinics” or “pri-
mary care services.”
We identified five systematic reviews, four meta-ana-
lyses, and 128 publications that included clinical practice
guidelines, clinical trials, and cohort, case-control and
cross-sectional studies relevant to answering the scienti-
f i cq u e s t i o n .T h ec r i t e r i ao fS a s l o ww e r eu s e dt os c r u t i -
nize and classify the literature according to the study
type and the level of evidence [20].
The systematic literature review allowed the identifica-
tion of three key components of the process delivered to
climacteric stage women: health promotion, screening,
and treatment. Within each component, the critical
activities to achieve a positive effect on women’sh e a l t h
were identified. The research group proposed 16 indica-
tors to evaluate the quality of the process of care
ii) An expert panel was integrated by two gynecolo-
gists who specialized in climacteric and menopause, two
health systems researchers, and two family doctors. All
had proven experience in clinical and health system
research, and in the development of clinical guidelines/
indicators. Each panelist received by e-mail the informa-
tion about the study objectives, a list of proposed indica-
tors, and the relevant literature. Panelists were asked to
validate the indicators by assigning a value from 1 to 9
(1 = definitely not valid and 9 = definitely valid). The
classification of the validity of the indicators followed
the criteria of Shekelle [21]. The panelists had to use
these criteria to individually rate the proposed indica-
tors. To consider an indicator valid, the median panel
rating was set to ≥ 7. This decision was in accordance
with a published study [21].
After two e-mail rounds of ranking, one vis-à-vis
meeting, and a review for coherence and content valid-
ity, a final set of 14 indicators was integrated (Table 1).
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Indicator Formula
I. Health promotion
1. Counseling about climacteric stage and menopause in the last
year
Number of climacteric stage women who received counseling about climacteric
stage, menopause and self-care related activities by the family doctor or other
health professionals, in the last year/Total number of women in the sample × 100
2. Nutritional counseling in the last year Number of climacteric stage women who received nutritional counseling by the
family doctor or other health professionals, in the last year/Total number of
women in the sample × 100
3. Advice on regular leisure time physical activity in the last year Number of climacteric stage women who received advice on regular leisure time
physical activity by the family doctor or other health professionals, in the last
year/Total number of women in the sample × 100
4. Smoke cessation counseling in the last year Number of current smokers climacteric stage women who received smoke
cessation counseling by the family doctor or other health professionals, in the last
year/Total number of actively smoking women in the sample × 100
II. Screening
1. Deliberate search of climacteric symptoms in the last year Number of climacteric stage women who were asked by the family doctor about
climacteric symptoms in the last year/Total number of women in the sample ×
100
2. Screening for overweight and obesity by calculating the body
mass index (BMI) in the last year
Number of climacteric stage women who received overweight and obesity
screening through the BMI calculation by the family doctor in the last year/Total
number of women in the sample × 100
3. Screening for hypertension by measuring the systolic and
diastolic blood pressure in the last year
Number of climacteric stage women that received hypertension screening
through measuring the systolic and diastolic blood pressure by the family doctor
or other health professionals, in the last year/Total number of women in the
sample × 100
4. Screening for diabetes by measuring fasting plasma glucose in
the last year
Number of climacteric stage women who received diabetes screening through
fasting plasma glucose measurement, in the last year/Total number of women in
the sample × 100
5. Screening for breast cancer through mammography in the
last 2 years
Number of climacteric stage women who received breast cancer screening
through mammography, in the last 2 years/Total number of women in the
sample × 100
6. Screening for cervical cancer through Pap test in the last 3
years in women without a history of total hysterectomy
Number of climacteric stage women without a history of total hysterectomy for
benign disease who received cervical cancer screening through Pap test, in the
last 3 years/Total number of women in the sample without a history of total
hysterectomy × 100
III. Treatment
1. Appropriate indication of oral hormone therapy (HT) a) Number of women with moderate or severe vasomotor symptoms 7/day ≥ (at
the time of the interview or the time to start oral HT) and without HT
contraindications, who receive oral HT
b) Number of women with moderate or severe vasomotor symptoms <7/day(at
the time of the interview or the time to start oral HT), or with mild symptoms or
without vasomotor symptoms who do not receive oral HT/Total number of
women in the sample × 100
2. Appropriate indication of vaginal HT a) Number of women with moderate or severe vaginal atrophy symptoms and
without oral HT who receive vaginal HT
b) the number of women without moderate to severe vaginal atrophy symptoms
or with oral HT who do not receive vaginal HT/Total number of women in the
sample × 100
3. Appropriate prescription of oral HT Number of women receiving oral HT prescription appropriately according to the
drug scheme, dose, schedule and duration of the treatment/Total number of
women in the sample receiving oral HT × 100
4. Information on risks and benefits of oral HT Number of women who were prescribed oral HT and who received information
about its purpose, benefits and risks/Total number of women in the sample
receiving oral HT × 100
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From November 2008 to March 2009, we conducted a
cross-sectional study in two Instituto Mexicano del
Seguro Social (IMSS) family medicine clinics (FMC)
located in Mexico City. The FMC were randomly
selected from the list of existing FMC in Mexico City.
O n ec l i n i cw a si nt h es o u t ho ft h ec i t ya n dt h eo t h e ri n
the north. Both clinics had similar characteristics, such
as the number of examining rooms and people covered.
The IMSS is a social security system for workers in
the formal market; ~48 million Mexicans are affiliated
with this institution [22].
The study population was women in climacteric stage
aged 45-59 years attending the FMC. To identify these
women we used the definition of the “Clinical Practice
Guideline on the Menopause and Postmenopause” [2]; also
we took into account that the mean age in which the
menopause occurs among Mexican women is 48 years
[23]. Besides the age interval, we also asked postmenopau-
sal candidates the date of the last menstrual period and we
only included participants who had their last period no
longer than eight years ago. Other inclusion criteria were:
at least three visits to the family doctor in the last year; not
suffering from type 2 diabetes, hypertension, depression,
and/or cancer; being with a stable life partner and agreeing
t op a r t i c i p a t ei nt h es t u d yb ys i g n i n gt h ei n f o r m e dc o n s e n t .
Study variables
The dependent variable was HR-QoL, and this was mea-
sured with the Cervantes scale [24]. This scale is a spe-
cific HR-QoL instrument for menopausal women. The
scale has 31 questions and covers four domains: meno-
pause and health, psychological domain, sexuality, and
couple relationship. The highest value for the global
score is 155 points, which means low HR-QoL, and the
lowest value is 0, which means high HR-QoL.
The independent variable was quality of care, which
was measured by ascertaining the percentage of recom-
mended care received [25]. This was estimated for each
care process component: health promotion, screening,
and treatment (Table 1). It was obtained by calculating
as i m p l ep r o p o r t i o n ,w i t ht h es u mo fi n d i c a t o r st h a t
women received as the numerator and the total number
of the recommended indicators as the denominator.
The covariates were:
a) Women’s general characteristics: Age, schooling,
and employment status, which included whether she
was involved in paid work.
b) Lifestyle: Healthy diet [26-28] which included the
daily consumption of fruits, vegetables, and dairy pro-
ducts, and non-consumption of carbonated beverages;
leisure time physical activity (PA) [29] where regular
was defined as moderate intensity if done for ≥ 30
minutes/day ≥ 5 days/week or vigorous intensity if
done three times a week with a duration of 20 minutes
per session, irregular was defined as carrying out less
than regular PA, or inactivity. Smoking status was
focused on current smokers and we registered the
number of cigarettes actually smoked per day among
those that answered positively. Alcohol consumption
was initially classified as non-drinkers (never drink
alcohol), occasional drinkers (drink rarely or less than
once a week), moderate drinkers (from 1 to 14 drinks
per week) and heavy drinkers (more than 14 drinks
per week) [30]. It has been reported that moderate
alcohol consumption has a positive association with
HR-QoL in middle aged women [31]; therefore, we
combined non-drinkers and occasional drinkers in a
single group and presented the data for moderate alco-
hol consumption only.
c) Nutritional status was measured by body mass
index (BMI) and classified into groups of normal
weight (BMI of 18.5-24.9 kg/m
2), overweight (BMI
of 25.0 to 29.9 kg/m
2), or obese (BMI ≥ 30.0 kg/m
2).
d) Social support (SS) was measured by applying the
DUKE-UNC-11 questionnaire [32]. This question-
naire evaluates confidential SS (possibility of having
people to communicate with) with a minimum score
of 7 points (low confidential SS) and a maximum
score of 35 points (high confidential SS); and affective
SS (demonstration of love, affection, and empathy)
with a minimum score of 4 (low affective SS) and a
maximum score of 20 points (high affective SS).
e) Medical and reproductive history: Presence of
chronic diseases, number of pregnancies and living
children, and menopause (one year after the last men-
strual period). Type of menopause was classified as
natural or surgical, age at onset of menopause; time
elapsed since menopause, presence and type of climac-
teric symptoms, and number of visits with the family
doctor in the last year. The severity of vasomotor
symptoms and vaginal atrophy symptoms was classi-
fied using the criteria proposed by the Department of
Health and Human Services Food and Drug Adminis-
tration [33], which are based upon women’s self-report,
and define the symptoms as mild, moderate, or severe.
f) Satisfaction with care received at the FMC was
measured with the general question of how satisfied
are you with the care you have received at the FMC?
The possible answers were very satisfied, satisfied,
neither satisfied nor unsatisfied, unsatisfied, and very
unsatisfied.
Sample size
We estimated a sample size of 400 women to evaluate
the possible association between HR-QoL and quality of
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mula to test the mean of a normal distribution [34]. A
mean decrease of at least 5 points on the global Cer-
vantes scale score per 10% increase in the quality of
care received was considered to be clinically relevant.
The assumptions included a mean global HR-QoL score
of 51.75 points (standard deviation of 23.1 points) [24],
a error = 0.05, 80% power, and 10% of possible non-
respondents (this means that a respondent answered
less than 80% of the questionnaire).
Study description
In each FMC, the nurse identified candidates in the
waiting room, explained the purpose of the study and of
the interview, and asked for her signed informed con-
sent. If the candidate agreed to participate, the nurse
performed the interview. The questionnaires used dur-
ing the interview were the Cervantes scale, the DUKE-
UNC-11 questionnaire, and a structured questionnaire
to collect general information and data to measure qual-
ity of care.
All questionnaires, including the Cervantes scale, were
pretested in 25 women in climacteric stage regarding
their understanding of the questions. The supervisory
nurse and/or one of the researchers (SVD) reviewed the
previous year’s clinical notes in the electronic medical
record to verify the care that each woman received.
The project was approved by the National Research
and Ethics Committee of the IMSS (number 2008-785-
014).
Statistical analysis
The descriptive analysis consisted of obtaining measures
of central tendency and dispersion for quantitative vari-
ables; in the case of categorical variables, absolute and
relative frequencies were obtained.
For the descriptive analysis of the HR-QoL, the mean
and standard deviation (SD) of global and particular
domain scores were obtained. We also categorized HR-
QoL global score and domain scores into: 1) low HR-
QoL, severe problem level (+2SD); 2) moderately low
HR-QoL, high problem level (+1SD and +2SD); 3) regu-
lar HR-QoL, low-medium problem level (+1SD and
-1SD); and 4) high HR-QoL, without problems (-1SD)
[23]
The association between global HR-QoL score and the
percentage of recommended care received for each com-
ponent of care (health promotion, screening and treat-
ment), as well as for each of the covariates was
evaluated through the Spearman correlation test.
To determine the magnitude of the adjusted associa-
tion between HR-QoL global score and each component
of quality of care, we used multiple linear regression
analysis. The model included conceptually relevant vari-
ables (schooling, confidential and affective support, lei-
sure time physical activity, healthy diet, presence of
chronic disease, body mass index, menopause, and
satisfaction with health care) that resulted in p ≤ 0.20 in
the bivariate statistical analysis. The method used for
modeling was backwards. The covariate presence/
absence of menopause was included as an adjustment
variable and it was not statistically significant, although
given its clinical importance it was maintained during
the modeling process. It was also tested if menopause
influenced the association of interest (relationship
between HR-QoL global score and each component of
quality of care). The analysis tested the interactions
between each component of quality of care and meno-
pause; such interactions were not statistically significant
and were not included in the final model.
Once the final model was obtained, the error terms
were generated, the assumptions of linearity, normality,
and equal variance were tested, and the goodness-of-fit
of the regression line was confirmed.
The analysis was performed with the Stata 8.0 statisti-
cal software (Stata 8.0, Stata Corp; College Station, TX).
Results
A total of 424 women met the inclusion criteria, of
which 2% refused to participate due to lack of time to
answer the interview questions. Of the 416 women
interviewed, 6 (1.4%) were excluded because they had
no medical notes of consultations during the last year in
their electronic medical records. The final analysis
included 410 women.
General characteristics, lifestyle, nutritional status, and
social support (Table 2)
The median age was 49 years, and the median schooling
was at secondary level. Of the respondents, 64.9% were
devoted to home and had no paid work.
As for lifestyle, the results show that most of women
had an unhealthy lifestyle; one in five women reported
having a healthy diet, and one in four reported regular
physical activity. Only 6.7% had both a healthy diet and
regular leisure time physical activity; 18.3% were current
smokers, they smoked a median of three cigarettes per
day. Most of interviewees were non-drinkers or occa-
sional drinkers, only 2% reported moderate consump-
tion. It was noted that a high proportion of participants
were overweight or obese.
On average, the interviewees received moderate social
support. The mean score for confidential support was
23.1 on a scale of 7 to 35 points and the mean score for
emotional support was 15.5 points on a scale of 4 to 20
points.
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symptoms (Table 3)
Half of participating women suffered from one chronic
condition, mainly musculoskeletal system diseases
(41.9%), and nutritional and metabolic disorders such as
dyslipidemia (19.0%).
As for reproductive history, the median number of
pregnancies and living children was three. Half of the
participants were menopausal, of which most had nat-
ural menopause. The median age at natural menopause
was 49 years and at surgical menopause was 45.5 years;
t h em e d i a nt i m ee l a p s e ds i n c em e n o p a u s ew a st h r e e
years. The most frequent climacteric symptoms were
changes in the menstrual cycle, hot flashes, sweating,
and dyspareunia; very few reported having moderate or
severe vasomotor symptoms, with a frequency of 7 or
more times a day; 22% had moderate to severe symp-
toms of vaginal atrophy. Women attended a median of
six visits to their family doctors in the last year.
Quality of care and satisfaction with care (Table 4)
The quality of care was assessed in three domains: health
promotion, screening, and treatment. Regarding health
promotion, a low percentage of participants had received
counseling about climacteric and menopause, nutrition,
leisure time physical activity, and smoking cessation.
The screening component showed important limita-
tions in several components. The family doctor asked
about climacteric symptoms in 37.8% of participants;
ascertainment of overweight and obesity were registered
in 3.4%, and screening for breast cancer in 42.2%.
Hypertension, diabetes, and cervical cancer screening
tests were performed in most women (99.3%, 88.3%, and
91.9%, respectively).
The treatment component indicated that most women
had appropriate indication of vaginal and oral HT (94.6%
and 81.0%, respectively). While 51.6% of 31 women
receiving oral HT had an appropriate prescription in
terms of scheme, dose, and time schedule, 38.7% had
received information about the risks and benefits of HT.
The health promotion component had the lowest
mean percentage of recommended care (24.1%), while
the treatment component had the highest (86.6%). Most
of the interviewed women (64.9%) reported being satis-
fied with the care received at the FMC.
Health-related quality of life (Figure 1)
Women rated their global HR-QoL as follows: high HR-
QoL, 15.1%; regular HR-QoL, 67.6%; moderately low
HR-QoL, 13.4%; and low HR-QoL, 3.9%. The mean glo-
bal HR-QoL score was 50.1 points (SD 24.7). The analy-
sis within the domains shows that more women in the
couple relationship domain reported high HR-QoL
(32.3%) compared with the other domains; in the sexual
domain, nobody reported low HR-QoL.
Relationship between health-related quality of life and
quality of care (Table 5)
The quality of treatment was significantly associated
with a better rating of global HR-QoL after adjusting for
other variables. The higher mean percentage of recom-
mended care received in the treatment component
reduced the mean global HR-QoL score on the Cer-
vantes scale (coefficient -0.28, P < 0.0001). This means
that for each 10 percentage points more of recom-
mended care received in the treatment component, the
rate of HR-QoL improved by 2.8 points on the Cer-
vantes scale. The association between HR-QoL and the
health promotion and screening components was not
statistically significant.
Discussion
The health of women in the climacteric stage is a com-
plex matter that requires further attention from health
services [8]. Some of the health problems that a climac-
teric woman suffers can be prevented or timely diag-
nosed, thus allowing the control or mitigation of the
potential consequences. Promoting high quality care
based on scientific evidence is critical; this helps women
to age in better health.
Table 2 General characteristics, lifestyle, nutritional
status, and social support
Variables n = 410
n (%)
I. General characteristics
Years of age, median (minimum- maximum) 49 (45-59)
Years of schooling, median (minimum- maximum) 8 (0-20)
Paid work 144 (35.1)
II. Lifestyle
Healthy diet 85 (20.7)
Leisure time physical activity
Regular 102 (24.9)
Irregular 67 (16.3)
Inactivity 241 (58.8)
Current smokers 75 (18.3)
Number of cigarettes per day, median
(minimum- maximum)
3 (1-15)
Moderate alcohol intake 8 (2.0)
III. Nutritional status
Body mass index, kg/m
2, mean ± SD 29.1 ± 4.3
Normal weight 70 (17.1)
Overweight 189 (46.1)
Obesity 151 (36.8)
IV. Social support
Confidential, mean ± SD 23.1 ± 6.5
Affective, mean ± SD 15.5 ± 3.7
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health promotion, screening, and treatment to assess the
quality of the process of care that climacteric stage
women receive in family medicine clinics. The indicators
should be feasible, available, and continuous. The infor-
mation for the present study came from two sources:
interviews with climacteric stage women and medical
records. Combining both sources provided information
that is more reliable but increased the cost of data col-
lection since trained personnel was required. In practice,
these indicators allowed the analysis of the quality of
care process with a swift and replicable methodology.
The evaluation of the quality of care pointed out flaws
in the processes of health promotion, screening, and
treatment. This finding is similar to the results of other
studies reporting that users receive only about half of
the recommended actions [35,36].
Health promotion interventions for climacteric stage
women include motivation to quit smoking, to follow a
healthy diet, and to do regular leisure time physical
activity. Carrying out these activities improves their
health status, reduces mortality due to chronic diseases,
and maintains bone mineral density and muscle strength
[26-28,37,38]. Counseling about climacteric stage
increases women’s knowledge about it and receptiveness
about self-care. Informed women can cope better with
the physiological and emotional changes that occur at
this stage and improve their lifestyle [39,40]. In our
study, the evaluation of health promotion revealed ser-
ious limitations. Only one out of every ten women fol-
lowed a healthy diet and did regular leisure time
physical activity. Most of those with unhealthy lifestyles
had not received information to improve it.
In family medicine clinics, all members of the health
team should perform health promotion activities: medi-
cal doctors, nurses, social workers, nutritionists, etc. Ide-
ally, these activities should be complementary, and the
health team members should reinforce them continually.
Previous studies performed at IMSS have reported that
health promotion is inadequate and requires substantial
improvements [41].
Screening of diseases allows timely diagnosis and
treatment, thus increasing the probability of better
health outcomes. The present study showed that women
underwent only half of the recommended screening
activities. Screening for overweight/obesity was poor,
despite it being easy to perform and the high prevalence
of obesity among Mexican women [42]. This finding
suggests the need to encourage health services to
improve the screening activities and to educate women
in this age group to increase the informed demand for
preventive care.
During the last years, the appropriate indication and
prescription of hormone therapy have been debated
[43]. Evidence-based clinical guidelines are available for
managing climacteric women. These guides provide
recommendations for the indication and appropriate use
of hormone therapy, while reducing the risk of adverse
events. In our study, we found that the treatment
component was close to the current recommendations,
but only half of the women were receiving appropriate
prescription of oral HT.
Table 3 Medical and reproductive history, climacteric
symptoms, and number of consultations with family
doctor
Variable n = 410
n (%)
I. Medical and reproductive history
Presence of chronic disease 202 (49.3)
Number of pregnancies, median (min- max) 3 (1-9)
Number of living children, median (min- max) 3 (0-9)
Menopause 224 (54.6)
Type of menopause n = 224
Natural 162 (72.3)
Surgical 62 (27.7)
Age in which menopause happened, median
(min- max)
n = 224
Natural 49 (38-56)
Surgical 45.5 (38-53)
Time elapsed after menopause, years 3 (0-8)
II. Climacteric symptoms n = 410
Hot flashes 205 (50.0)
Sweating 181 (44.1)
Insomnia 169(41.2)
Dysuria 91 (22.2)
Vaginal dryness 161 (39.3)
n = 186
Changes in the menstrual cycle in pre-menopause
women
98 (52.6)
n = 352
Dyspareunia and/or vaginal bleeding in sexual active
women
101 (28.7)
Severity and frequency of vasomotor symptoms n = 410
Absence 192 (46.8)
Mild 46 (11.2)
Moderate
< 7/day 129 (31.5)
≥ 7/day 2 (0.5)
Severe
< 7/day 32 (7.8)
≥ 7/day 9 (2.2)
Severity of vaginal atrophy symptoms n = 410
Absence 219 (53.4)
Mild 101 (24.6)
Moderate 40 (9.8)
Severe 50 (12.2)
III. Number of consultations with a family doctor
during the last year, median (min- max)
6 (3-20)
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Page 7 of 12Table 4 Quality of care
† and satisfaction with care
Variable n = 410
I. Health promotion n (%)
1. Counseling about climacteric and menopause 52 (12.7)
2. Nutritional counseling 59 (14.4)
3. Advice on regular leisure time physical activity 178 (43.4)
4. Smoke cessation counseling in current smokers n=7 5
23 (30.7)
II. Screening n = 410
1. Deliberate search of climacteric symptoms 155 (37.8)
2. Screening for overweight/obesity 14 (3.4)
3. Screening for hypertension 407 (99.3)
4. Screening for diabetes 362 (88.3)
5. Screening for breast cancer 173 (42.2)
6. Screening for cervical cancer in women without total hysterectomy n = 347
319 (91.9)
III. Treatment n = 410
1. Appropriate indication of oral HT 388 (94.6)
a) Women with moderate or severe vasomotor symptoms ≥ 7/day (at the time of the interview or the time to start oral HT)
and without contraindications for HT
n=3 7
oral HT indicated appropriately 20 (54.0)
oral HT not indicated 17 (46.0)
b) Women with moderate or severe vasomotor symptoms <7/day (at the time of the interview or the time to start oral HT),
with mild symptoms or without vasomotor symptoms
n = 373
oral HT indicated 5 (1.4)
oral HT not indicated appropriately 368 (98.6)
2. Appropriate indication of vaginal HT 332 (81.0)
a) women with moderate or severe vaginal atrophy symptoms and without oral HT n = 87
vaginal HT indicated appropriately 9 (10.3)
vaginal HT not indicated 78 (89.7)
b) women without moderate to severe vaginal atrophy symptoms or with oral HT n = 323
vaginal HT indicated 0 (0.0)
vaginal HT not indicated appropriately 323 (100.0)
Women receiving oral HT n=3 1
3. Appropriate prescription of oral HT 16 (51.6)
4. Information on risks and benefits of oral HT 12 (38.7)
n = 410
Percentage of recommended care received % mean ± SD
Health promotion 24.1 ± 28.1
Screening 59.5 ± 16.8
Treatment 86.6 ± 22.9
Satisfaction with care received at the FMC n (%)
Very satisfied 66 (16.1)
Satisfied 200 (48.8)
Neither satisfied nor unsatisfied 90 (22.0)
Unsatisfied 41(10.0)
Very unsatisfied 13 (3.2)
† For complete information about the formula of each quality of care indicator, please see Table 1.
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pose, benefits, and potential adverse events of HT con-
tributes to increased adherence to HT and the timely
identification of the adverse events. The flaws of the
treatment component, such as inappropriate prescrip-
tion and poor information, stress the need to update the
medical staff and to evaluate the quality of care in a
continuous way. In addition, it is advisable to search for
feasible alternatives to motivate providers to deliver
high-quality care. The use of incentives, either in kind
or monetary, is a viable approach. In addition, the defi-
nition of standards is necessary as this allows the quality
to be evaluated in a reliable way; our data would help in
defining the standards of care at the local level. The
implementation of standards of care and evaluation
activities should be tailored to the characteristics of the
services that are being evaluated.
In our study, we used the Cervantes scale to measure
HR-QoL because this scale comprehensively addresses
the main domains of the health of women in climac-
teric stage. The questionnaire was applied as rigorously
as possible, assuring that all participants understood
and answered all the questions. In our sample, the
mean value for the global HR-QoL score was similar
to those reported for Spanish women [24]. It is notice-
able that no woman reported severe problems in the
Figure 1 Health-related quality of life measured by Cervantes scale (n = 410).
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Page 9 of 12sexuality domain. It is possible that due to sensitive
nature of the subject, they were not completely open
to answer such question. In another study in Spain
that used the Cervantes Scale, it was observed that the
answers of women in the sexuality domain were differ-
ent when they were interviewed directly, than when
they answered anonymously the questionnaire. In the
open interview they minimized the problems in the
sexual domain [44]. In our study, all participants
answered to an interviewer. Our findings allow the
assumption that the Cervantes scale can be applied to
Mexican women but should be validated within the
Mexican context.
There is an ongoing trend toward ascertaining the
relationship between quality of care and health out-
comes [45,46]. The present study found that the treat-
ment component was associated with better global HR-
QoL. This can be due to the effect of the drugs on redu-
cing the climacteric symptoms, thus resulting on
improving HR-QoL in the short term; in contrast, the
positive effect of the health promotion and screening
components would happen in the long term. It is possi-
ble that the relationship between these components and
HR-QoL is not straightforward. A number of variables
intervene, such as changes in lifestyle, women’s endow-
ment, etc.
This cross-sectional study has several limitations. It is
possible that the evaluation of the quality of care is lim-
ited because, in Mexico, the women who use health ser-
vices often have a chronic illness and require specific
attention. In this study, the quality of care assessment
was limited to the climacteric stage and did not assess
the process of care for other health problems. The study
evaluated the quality of care only in IMSS-affiliated
women; this affects its external validity. It would be per-
tinent to consider the applicability of the indicators in
other health care institutions. This is reasonable because
quality measurements should consider the local condi-
tions. In addition, the probability of misclassifying the
indicators for evaluating the appropriate oral and vaginal
HT indication exists; each indicator combines two parts
1) appropriate indication for women who need this ther-
apy and 2) no indication for women who do not need it.
Because most of the women in the sample do not need
to receive either oral or vaginal HT, the results reflect
the proper “no indication” more, so the association
between HR-QoL and quality of care in the treatment
component was probably overestimated. Also, to evalu-
ate the HR-QoL we used the Cervantes scale, which has
questions about the couple relationship, which in turn
implies that the woman should have a partner. This
could represent a limitation in the generalizability of the
study, given that it has been reported in Mexico that
about 21% of women of this age do not have a partner
[41].
In conclusion, the indicators developed to measure the
quality of care process for climacteric stage women are
applicable and feasible. Its application in this study
showed that health care in this population is limited in
the health promotion, screening, and treatment compo-
nents. There is a positive association between the quality
of treatment and HR-QoL, which can encourage the
development of interventions aimed at improving the
performance of health services. It is advisable to con-
sider the possibility of designing future interventions
with a holistic approach toward improving the quality of
care for women at this stage.
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